Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

GALAPAGOS Aktie

 >GALAPAGOS Aktienkurs 
24.58 EUR    -0.5%    (Tradegate)
Ask: 24.54 EUR / 130 Stück
Bid: 24.38 EUR / 130 Stück
Tagesumsatz: 140 Stück
Realtime Kurs von 8 bis 22 Uhr!
GALAPAGOS Aktie über LYNX handeln
>GALAPAGOS Performance
1 Woche: +1,7%
1 Monat: -2,7%
3 Monate: +14,1%
6 Monate: -10,2%
1 Jahr: +5,4%
laufendes Jahr: -6,5%
>GALAPAGOS Aktie
Name:  GALAPAGOS N.V.
Land:  Belgien
Sektor:  Gesundheit
ISIN/ Wkn:  BE0003818359 / A0EAT9
Symbol/ Ticker:  GXE (Frankfurt)
Kürzel:  FRA:GXE, ETR:GXE, GXE:GR
Index:  AEX
Webseite:  https://www.glpg.com/
Marktkapitalisierung:  1640 Mio. EUR
Umsatz:  288.19 Mio. EUR
EBITDA:  -276.28 Mio. EUR
Gewinn je Aktie:  -2.74 EUR
Schulden:  10.86 Mio. EUR
Liquide Mittel:  3300 Mio. EUR
Umsatz-/ Gewinnwachstum:  20.1% / -
KGV/ KGV lG:  56.79 / 163.93
KUV/ KBV/ PEG:  5.57 / 0.58 / -
Gewinnm./ Eigenkapitalr.:  -58.83% / -6.36%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  GALAPAGOS
Letzte Datenerhebung:  06.07.25
>GALAPAGOS Eigentümer
Aktien: 65.9 Mio. St.
f.h. Aktien: 64.99 Mio. St.
Insider Eigner: 25.36%
Instit. Eigner: 31.57%
>GALAPAGOS Peer Group

UCB
 
23.06.25 - 08:36
Galapagos appoints Aaron Cox as CFO (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
23.06.25 - 07:33
Galapagos Appoints Aaron Cox as Chief Financial Officer (GlobeNewswire EN)
 
Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership ...
18.06.25 - 22:03
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101 (GlobeNewswire EN)
 
Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused with fresh CAR-T cells, and 93% were treated within seven days of manufacturing...
12.06.25 - 22:03
Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL (GlobeNewswire EN)
 
Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin's Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities...
27.05.25 - 22:36
Galapagos Creates New Subscription Right Plan (GlobeNewswire EN)
 
Mechelen, Belgium;  May 27, 2025, 22:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its  Board of Directors created 925,000 subscription rights under a new subscription right plan....
14.05.25 - 22:03
Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101 (GlobeNewswire EN)
 
Mechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that new data from our ongoing ATALANTA-1 Phase 1/2 study of GLPG5101 in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) have been accepted for oral presentations at the 2025 European Hematology Association (EHA) Congress taking place June 12-15, 2025, in Milan, Italy, and the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland the following week....
13.05.25 - 20:30
Biotech-Firma Galapagos vollzieht radikale Kehrtwende (Sharedeals)
 
Radikaler Strategieschwenk bei Galapagos: Der Biotech-Konzern bläst die geplante Ausgliederung ab und verabschiedet CEO Stoffels. Was dieser Kurswechsel für die Zukunft des krisengeplagten Unternehmens und seine Anleger bedeutet. In der Welt der Biotech-Unternehmen sorgt derzeit Galapagos für Aufsehen. Der belgische Konzern, der trotz 25-jähriger Firmengeschichte noch keine zugelassene Therapie vorweisen kann, nimmt eine drastische Strategieänderung […] The post Biotech-Firma Galapagos vollzieht radikale Kehrtwende first appeared on sharedeals.de....
13.05.25 - 13:27
Galapagos to reevaluate spinoff plans; names new CEO (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.05.25 - 07:39
Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes (GlobeNewswire EN)
 
Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments...
24.04.25 - 17:36
Galapagos NV outlines plans for pivotal CAR-T trials and SpinCo separation in 2025 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
23.04.25 - 22:06
Galapagos GAAP EPS of -€2.35, revenue of €75M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
21.04.25 - 22:21
Galapagos CEO to retire; Henry Gosebruch named as founding CEO of newly created SpinCo (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
21.04.25 - 22:12
Galapagos Announces Executive Leadership Updates (GlobeNewswire EN)
 
Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as founding CEO of newly created SpinCo ...
15.04.25 - 16:00
Galapagos′ CFO announces departure (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
15.04.25 - 07:33
Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025 (GlobeNewswire EN)
 
Mechelen, Belgium; April 15, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced the departure of its CFO and COO, Thad Huston, effective as of August 1, 2025. Mr. Huston has decided to leave the company and return to the U.S. for personal and professional reasons. Mr. Huston joined Galapagos NV in 2023 from Kite Pharma, Inc., to support Galapagos' transformation into a cell therapy company. The company expects to announce Mr. Huston's successor in the coming months.Paul Stoffels1, MD, CEO and Chair of the Board of Directors of Galapagos, said “Over the past two years, Thad has worked on the transformation of Galapagos into a focused cell therapy business leveraging our unique decentralized cell therapy platform to deliver fresh, stem-like early memory CAR-T therapy with a vein-to-vein time of seven days. Thad wil...
04.04.25 - 15:12
Galapagos Named Top Travel Destination for North Americans in Ultimate Showdown (PR Newswire)
 
Exodus Adventure Travels Announces Results of Major March Bracket Competition NEW YORK, April 4, 2025 /PRNewswire/ -- As millions of North Americans engage in their championship brackets, Exodus Adventure Travels, the leading international small group guided tour company, today announced......
27.03.25 - 21:03
Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders′ Meeting (GlobeNewswire EN)
 
Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders' Meeting (AGM) to be held on Tuesday, April 29, 2025 at 14:00 CET at the registered office of the Company. ...
12.03.25 - 14:30
CELEBRITY CRUISES′ BUCKET LIST GALAPAGOS EXPEDITIONS ARE NOW OPEN FOR BOOKING IN 2027 (PR Newswire)
 
Guests on every sailing can take part in the cruise line's one-of-a-kind conservation project, Rewilding Galapagos, which is celebrating 10 years. MIAMI, March 12, 2025 /PRNewswire/ -- Celebrity Cruises' award-winning Galapagos expeditions on Celebrity Flora are now available for booking......
24.02.25 - 22:03
Galapagos to Present at Upcoming Investor Conferences (GlobeNewswire EN)
 
Mechelen, Belgium; February 24, 2025, 22:01 CET – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that its management will present at the following investor conferences in March:TD Cowen 45th Annual Healthcare Conference Date: Tuesday, March 4, 2025Location: Boston, MACorporate Presentation: 1:50 - 2:20 PM ET / 7:50 - 8:20 PM CETLive Webcast Link: HereBarclays 27th Annual Global Healthcare ConferenceDate: Wednesday, March 12, 2025Location: Miami, FLCorporate Presentation: 11:00 - 11:25 AM ET / 5:00 - 5:25 PM CETLive Webcast Link: HereA live webcast of the presentations can also be accessed on the Investors page of the Company's website at www.glpg.com/investors. Replays of the webcasts will be available following the completion of the event and will be archived for up to 90 days.About GalapagosWe are a biotechnology company with operations in Europe and the U.S. dedicated to...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Es geht nichts über ein ruhiges Leben, wie der Mann sagte, als er die Stelle eines Leuchtturmwärters annahm. - Charles Dickens
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!